![]() January 4, 2017, the aggregate implied value of the consideration paid in connection with the acquisition was approximately $23.6 billion, including approximately $13.6 billion inĬash and approximately $10 billion in Abbott common shares. Based on the closing Abbott share price on January 4, 2017, Abbott completed the acquisition of St. Jude Medical, Inc., a global medical device manufacturer. October 3, 2017, Abbott completed the acquisition of Alere, Inc., a diagnostic device and service provider, for an aggregate consideration of approximatelyįebruary 27, 2017, Abbott completed the sale of Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. Abbott's* principal business is the discovery, development, manufacture,Īnd sale of a broad and diversified line of health care products.Ībbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and The Proxy Statement will be filed on or aboutĪbbott Laboratories is an Illinois corporation, incorporated in 1900. Portions of the 2019 Abbott Laboratories Proxy Statement are incorporated by reference into Part III. Number of common shares outstanding as of January 31, 2019: 1,756,470,269 The aggregate market value of the 1,710,210,374 shares of voting stock held by nonaffiliates of the registrant, computed by reference to the closing priceĪs reported on the New York Stock Exchange, as of the last business day of Abbott Laboratories' most recently completed second fiscal quarter (June 30, 2018), was $104,305,730,710. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialĪccounting standards provided pursuant to Section 13(a) of the Exchange Act. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. ![]() Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, orĪn emerging growth company. Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of thisĬhapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of thisįorm 10-K or any amendment to this Form 10-K. ![]() ![]() Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesĮxchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Name of Each Exchange on Which Registered
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |